Skip to main content

Table 2 Patients receiving scheduled treatment per cycle

From: Influence of complete administration of adjuvant chemotherapy cycles on overall and disease-free survival in locally advanced rectal cancer: post hoc analysis of a randomized, multicenter, non-inferiority, phase 3 trial

  Capecitabine Fluorouracil
Adjuvant Cohort1
 1 107 (98%) 109 (100%)
 2 105 (96%) 106 (97%)
 3 102 (94%) 101 (93%)
 4 99 (91%) 96 (88%)
 5 98 (90%) 92 (84%)
 6 90 (83%)
Neoadjuvant Cohort2
 1 66 (93%) 71 (99%)
 2 50 (70%) 46 (64%)
 3 46 (65%) 38 (53%)
 4 42 (59%) 35 (49%)
 5 40 (56%) 32 (44%)
 6 37 (52%)
  1. Data are n (%)
  2. 1n = 109 Capecitabine, n = 109 Fluorouracil;
  3. 2n = 71 Capecitabine, n = 72 Fluorouracil